Please ensure Javascript is enabled for purposes of website accessibility

Why NRx Pharmaceuticals Stock Jumped 11.8% Today

By Keith Speights – Aug 18, 2021 at 5:27PM

Key Points

  • NRx stated that the Data Safety Monitoring Board, in a late-stage study of Zyesami combined with Veklury, has found no new safety issues and is recommending that enrollment in the study continues.
  • The company awaits the potential U.S. Emergency Use Authorization of Zyesami in treating severe COVID-19.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company provided a positive update from a clinical study evaluating its COVID-19 therapy Zyesami.

What happened

Shares of NRx Pharmaceuticals (NRXP 5.50%) jumped 11.8% as of the market close on Wednesday. The big gain came after the company announced positive safety findings from a late-stage study evaluating its drug Zyesami in combination with Gilead Sciences' Veklury in treating hospitalized patients with acute respiratory failure due to COVID-19.

So what

NRx didn't provide details from the late-stage study of Zyesami and Veklury. However, the company stated that the study's Data Safety Monitoring Board has identified no new safety issues and is recommending moving forward with enrollment in the trial.

Gloved hand between fallen wood dominoes spelling "COVID-19" and standing wood dominoes.

Image source: Getty Images.

That was enough for investors to drive the biotech stock higher today. NRx reported results from a phase 2b/3 study in July that found that Zyesami helped prevent cytokine storms in COVID-19 patients. Cytokine storms occur when the body produces too many cytokine proteins, which can result in serious organ damage. 

Now what

Although the update from NRx was good news, the big milestone that investors are waiting for is U.S. Emergency Use Authorization (EUA) for Zyesami. NRx submitted its EUA filing on May 31, 2021.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NRx Pharmaceuticals, Inc. Stock Quote
NRx Pharmaceuticals, Inc.
$1.15 (5.50%) $0.06
Gilead Sciences Stock Quote
Gilead Sciences
$86.26 (0.98%) $0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.